RespireRx Pharmaceuticals Inc (RSPI)

[enemem]

"you also don't want to singlemindedly pursue an indication that could become moot. "

Nobody's recommending single-mindedly pursuing the low-impacts for AD. It is highly unlikely to be "disease modfying", but if it has palliative effects, it is already head and shoulders above everything else out there. How can you pass this up?

If there is a single-minded commitment to an indication, it is ADHD, not AD.

Why not start a trial to treat respiratory disfunction in
Rett's syndrome using low impacts? They have very nice preclinical data on this using a pretty good animal model, and there is virtually nothing else out there for these kids. Also, there is no "disease-modifying" anything with these kids: they have massive problems with their CNS, so it would be nice if something were done to ameliorate the one symptom that may be amenable to treatment. Approval of an IND (submitted to Neurology, likely) for an orphan indication would likely be easier to obtain than any kind of ADHD approval.

I'm not saying this is guarranteed, it's just that this kind of proposal merits consideration. Why isn't anything like this explicitly being put forward? The company desperately needs to establish ampakine safety, and this might be a route.